AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05739760 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Poem book about relational health
Description: Poem book will consist of illustrations, poetry, and tips for parents on how to resolve their child's upset, their own upset, and to develop a stronger relationship. The study physician may read the book to the families at the visit. Then, families are instructed to read the book at least once, for as many times as the parent opts to.
Study NCT05739760 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Poem book about physical health and safety
Description: Poem book will consist of illustrations, poetry, and tips for parents on how to keep their child physically healthy and safe, and to avoid accidental injuries. The study physician may read the book to the families at the visit. Then families are instructed to read the book at least once, for as many times as the parent opts to.
Study NCT05865080 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 0.3 mg/kg of ketamine IV diluted to 10 ml followed by infusion 0.1 mg/kg/hr. as 20 ml solution before spinal anesthesia
Study NCT05865080 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study NCT06110728 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habit Change
Description: Participants assigned to the Habit Change arm will be asked to track behaviors related to their specific goals on a daily basis through the app and will be allowed to engage with the app freely. Goals can include things like reaching a step goal, sleeping for a certain number of hours, or making healthy food choices.
Study NCT04809272 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ParentChat for parents of children ages 2-17
Description: The programme will include text/audio messages, illustrated comics, videos, and activity assignments for parents to do with their children. Parents will be prompted to give feedback regarding successes and challenges applying these parenting skills via audio or text messages during the week.
Study NCT04674267 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phase 2 Intervention - Geriatric Co-Management
Description: Participants will complete an electronic fitness assessment questionnaire - once completed, they will receive a score of Robust, Pre-Frail or Frail. Those who are Pre-frail or Frail will be randomized to meet with a study geriatrician for geriatric co-management in addition to usual oncology care. All participants will be followed for a duration of 1 year.
Study NCT05221866 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Empowering patient to steer their pain management after surgery
Description: Prior to discharge from the hospital, patients will be approached regarding interest in the study with an introductory letter that describes the content and purpose of the study. Following informed consent, patients will be randomized to receive the consumer health informatics app (UControlPain) versus provision of an app with only data collection function (no educational components) in an intent-to-treat design. Randomization will be implemented via REDCap by the study coordinators so that all investigators will remain blind to group assignment. Further, information on which type of app was installed will not be shared with providers or patients.
Study NCT05221866 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Provider-facing prescription aid
Description: Providers will be given information to inform a patient-centered post-discharge pain management plan.
Study NCT06209489 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White cover
Description: * A white cover will be covered over the incubator during phototherapy.~* Baby massage will be applied during phototherapy.
Study NCT03971149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMPOWER
Description: EMPOWER includes 4 weekly home visit and 4 follow up booster phone calls every other week for the following 8 weeks. The trained nurse interventionist will address identified adherence barriers related to knowledge deficits about heart failure and its treatment including psycho-social barriers and logistic barriers with their primary care physician if necessary.
Study NCT05841446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: test apixaban tablets
Description: specification: 2.5 mg, manufacturer: Disha Pharmaceutical Group Co., Ltd., Shandong, China
Study NCT05841446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: reference apixaban tablets
Description: specification: 2.5 mg, manufacturer: Bristol-Myers Squibb Manufacturing Company, USA
Study NCT06229821 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Intrapulmonary Percussive Ventilation
Description: IPV applied at increasing intervals, starting every 6 hours, and ending at every 24 hours, for a total of 7 days.
Study NCT04638751 — intervention group
Intervention type: DRUG
Intervention: Immunotherapy
Description: Checkpoint inhibitor
Study NCT04638751 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy
Description: Any form of chemotherapy
Study NCT04722588 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Introducing clinical pharmacists to the interdisciplinary ED team.
Description: There will be two shifts, one shift from 08.00 - 15.00 and one from 12.00 - 19.00. Consequently, the hours of the day when the majority of patients arrives, are covered and the pharmacist capacity is doubled during the busiest time of the day. Early mornings are normally relatively slowed paced and the pharmacist may use this time to follow up on patients admitted during the night (from 19.00 - 08.00), in particularly those who have been admitted to wards without an assigned pharmacist.
Study NCT04638751 — intervention group
Intervention type: PROCEDURE
Intervention: CRC surgical resection
Description: Surgical resection to remove colorectal cancer
Study NCT04638751 — intervention group
Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: Standard-of-care colonoscopy for CRC screening
Study NCT05708924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT538
Description: FT538 IP at assigned dose level on Day 1, Day 8, and Day 15.
Study NCT05708924 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enoblituzumab
Description: Enoblituzumab 15 mg/kg IV begin on Day -6 and continuing once every 3 weeks beginning on Day 22 until disease progression or unacceptable toxicity - refer to Section 7.2.1 for timing of the enoblituzumab dose on Day 22 if steroid pre-meds are needed due to an infusion reaction with the 1st enoblituzumab dose as there is a 14 day ban on corticosteroid use after the last dose of FT538
Study NCT05289128 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: 10-sessions of anodal HD-tDCS ( tDCS 1x1, developed by Soterix Medical Inc.) associated to respiratory training; for 20 minutes (each session). It will be delivered a 3mA intensity electrical current accordingly 10/20 International System on cortical representation zone of left diaphragmatic motor cortex using HD-tDCS.
Study NCT05289128 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Control
Description: 10-sessions of anodal HD-tDCS( tDCS 1x1, developed by Soterix Medical Inc.) associated to respiratory training; for 20 minutes (each session) with a 3mA intensity.The device will provide a 30-second ramp-up followed immediately by a 30-second ramp down.
Study NCT05442671 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise intervention
Description: 16-week home exercise intervention, enriched by mobile health technology
Study NCT04955067 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnositic test
Description: The results of hip arthroscopy were taken as the gold standard, and MRI examination was taken as the research object
Study NCT05093998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV5080
Description: oral hard gelatin capsules
Study NCT05093998 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Hard gelatin capsules with a white body
Study NCT04800120 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen Therapy
Description: Delivery of 100% oxygen within a hyperbaric oxygen therapy chamber
Study NCT05387577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol Tablets
Description: Oral estradiol will be taken sublingually, 1 mg BID for 8 weeks
Study NCT05387577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal patch
Description: Estradiol patch therapy for 8 weeks
Study NCT05747274 — intervention group
Intervention type: DEVICE
Intervention: SRDK0921
Description: SRDK0921 is an IVD composed of IVD kit for qPCR (SRDK0921KIT) and a cloud-based software (SRDK0921SOFT). It is a class C, rule 3k, IVD according to Regulation (EU) 2017/746.
Study NCT05745649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercises
Description: Resistance exercises
Study NCT05745649 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ankle weights
Description: Ankle weights
Study NCT05171153 — intervention group
Intervention type: OTHER
Intervention: Densitometry with Trabecular Bone Score
Description: Conventional bone densitometry at the level of the proximal femur and lumbar spine (L1-L4) (anteroposterior and lateral) measured with a General Electric Prodigy Advance Full enCORE version 11.x equipment. With the data from the lateral densitometry, and using the VFA Dual Vertebral Assessment H8650DA/DM software, a quantitative morphometric analysis of the thoracolumbar vertebrae (T4-L4) will be carried out. Additionally, microarchitectural parameters of the lumbar spine will be evaluated with TBS (iNsight v3.0) and bone quality in the proximal femur with the DEXA-3D 3D-SHAPER v2.10.1 software. Vertebral fracture will be excluded from the DXA and TBS analysis of the spine.
Study NCT05171153 — intervention group
Intervention type: OTHER
Intervention: Quantitative Ultrasound of Calcaneus
Description: Quantitative bone ultrasound of calcaneus evaluated with a SONOST 3000, (OsteoSys Co, Korea).
Study NCT05171153 — intervention group
Intervention type: OTHER
Intervention: Laboratory test
Description: Analysis of general biochemical parameters and serum phospho-calcium metabolism, including: total calcium, albumin, phosphorus, 25-OH-vitamin D, intact PTH (iPTH), creatinine, estimated glomerular filtration rate, carboxy-terminal telopeptide of type I collagen ß-CTx (Crosslaps) and N-terminal propeptide of type I procollagen (P1NP).
Study NCT05547412 — intervention group
Intervention type: DEVICE
Intervention: NovaGuide 2 Intelligent Ultrasound System
Description: The NovaGuide 2 Intelligent Ultrasound system is an adjunctive mobile, non-invasive, non-ionizing radiation transcranial Doppler (TCD) diagnostic ultrasound system. The system contains a transcranial doppler ultrasound equipment combined with robotic mechanisms used to position ultrasound probes, which assist the user in the acquisition of cerebral blood flow velocity (CBFV) data via a patient's temporal acoustic windows.
Study NCT05700630 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FT538
Description: FT538 is an investigational off-the-shelf cryopreserved NK cell product derived from an iPSC that contains three functional modifications: 1) a novel high affinity, non-cleavable CD16 (Fc receptor) that maintains CD16 on the cell surface and remains fully functional after NK cell activation, thus augmenting ADCC; 2) an IL-15 receptor fusion that promotes NK cell activity and enhances cell persistence; and 3) the knock-out of CD38 expression prevent anti-CD38 antibody-induced fratricide.
Study NCT05700630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat is a histone deacetylase inhibitor (HDACi) that is FDA approved for the treatment of cutaneous T-cell lymphoma and, under investigation in HIV as disruptor of HIV latency.
Study NCT05696847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC
Study NCT05696847 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT05634486 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidisciplinary therapeutic approach (physiotherapy plus cognitive-behavioral therapy)
Description: Patients randomly allocated to this arm of intervention will receive an ambulatory therapy regime of twelve 60-minute physiotherapy sessions plus four 60-minute psychotherapy sessions throughout one month of treatment
Study NCT05634486 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Psychoeducation (Sham intervention)
Description: Patients randomly allocated to this arm of intervention will receive an ambulatory regime of four 60-minute non-organized psychoeducational sessions throughout one month of treatment.
Study NCT05512767 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Undergo self-manual lymphatic drainage
Study NCT05512767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consensus Auditory-Perceptual Evaluation of Voice
Description: Ancillary studies
Study NCT05512767 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Consensus Auditory-Perceptual Evaluation of Voice
Description: Ancillary studies
Study NCT05387577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol Tablets
Description: Oral estradiol 1 mg BID for 8 weeks
Study NCT05806021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: Intra-articular injection. For each group, the total injected will be 3 ml. For syringes containing triamcinolone acetonide, the missing volume will be filled with 0.9% isotonic saline
Study NCT05806021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: Intra-articular injection. For each group, the total injected will be 3 ml. For syringes containing triamcinolone acetonide, the missing volume will be filled with 0.9% isotonic saline
Study NCT05069285 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-help book
Description: information and advice given in the self-help book
Study NCT05069285 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sleep hygiene advice
Description: information and advice given on the sheet of paper with sleep hygiene
Study NCT05855486 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Saline eye drops
Description: Ocular drops used to facilitate the removal of ocular secretions in pediatric subjects
Study NCT06020001 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AP203 mixture (RESCOVIN®)
Description: Polyphenol-rich plant extracts Twice a day
Study NCT06020001 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice a day
Study NCT05386498 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: precured composite insert technique
Description: After curing of bonding agent a 2mm increment of composite will be placed on the gingival floor of the cavity and cured. a measured volume of composite(3mm height and 2mm width) will be cured outside the oral cavity on a flat plastic instrument for 40 seconds. a second increment of composite will be placed on the cavity and the precured composite will be pressed in the uncured increment and pressed outward against the matrix band and light cured for 20 seconds the rest of the cavity will be filled using the oblique layering technique.
Study NCT05386498 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contact making instrument
Description: a 1-2mm increment of the composite will be placed in the gingival floor of the proxial box.~a contact forming instrument will be placed in this uncured increment and an outward force will be applied using the instrument from the inside of the matrix band. The composite will then be cured for 20 seconds to achieve a tight contact.
Study NCT05386498 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incremental composite layering technique
Description: Increments will be placed in 1-2mm increments in oblique layering manner by a flat plastic instrument and condenser .Each increment will be cured for 20 seconds till the cavity is slightly overfilled.
Study NCT05032794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unrestricted diet before colonoscopy
Description: Free diet, without restrictions
Study NCT05032794 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1-day low residue diet
Description: To follow a diet low in residues / fiber. the day before the colonoscopy.
Study NCT05032794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisacodyl 5 MG
Description: If the participant is at risk of inadequate bowel cleansing, defined by a score of Dik et al ≥ 2 it will be given Bisacodyl 5 milgrams bid for 3 days.
Study NCT05032794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisacodyl 5 MG
Description: If the participant is at risk of inadequate bowel cleansing, defined by a score of Dik et al ≥ 2 it will be given Bisacodyl 5 milgrams bid for 3 days.
Study NCT05868161 — intervention group
Intervention type: DEVICE
Intervention: Pounce Thrombectomy System
Description: Non-surgical removal of thrombi and emboli from the peripheral arterial vasculature with the Pounce Thrombectomy System.
Study NCT05106946 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ThisCART22 cells
Description: 0.2-60 x 10\^6 CAR T cells per kg body weight
Study NCT04530747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin + PAP
Description: Subjects randomized to this arm will receive 500 mg capsules containing metformin extended release (XR). Metformin XR dosing will be 500 mg (1 x 500 mg) every evening (qPM) during Week 1, 1000 mg (2 x 500 mg) qPM during Week 2, 1500 mg (3 x 500 mg) qPM during Week 3, and 2000 mg (4 x 500 mg) qPM from Week 4 onwards.~Subjects will also be provided PAP (positive airway pressure) device for standard management of obstructive sleep apnea.
Study NCT04530747 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule + PAP
Description: Subjects randomized to this arm will receive 500 mg capsules containing placebo. Placebo dosing will be 500 mg (1 x 500 mg) qPM during Week 1, 1000 mg (2 x 500 mg) qPM during Week 2, 1500 mg (3 x 500 mg) qPM during Week 3, and 2000 mg (4 x 500 mg) qPM from Week 4 onwards.~Subjects will also be provided PAP (positive airway pressure) device for standard management of obstructive sleep apnea.
Study NCT06449170 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mango Ataulfo
Description: In this intervention, subjects consumed 150g of mango Ataulfo plus 150 ml of control beverage (Supportan® Drink Cappuccino). The addition of the control beverage has the purpose of providing energy intake and limiting the noise that the control beverage may contribute to the metabolomic profile in urine and serum.
Study NCT06449170 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Avocado Hass
Description: In this intervention, subjects consumed 120g of avocado hass plus 150 ml of a control beverage (Supportan® Drink Cappuccino). The addition of the control beverage provides energy intake and limits the noise that the beverage may contribute to the metabolomic profile in urine and serum.
Study NCT06449170 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nopal
Description: In this intervention, subjects consumed 300g of cooked nopal and 150 ml of control beverage (Supportan® Drink Cappuccino). The addition of the control beverage provides energy intake and limits the noise that the beverage may contribute to the metabolic profile in urine and serum.
Study NCT06449170 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 3 corn tortilla
Description: In this intervention, subjects consumed 3 corn tortillas and 150 ml of control beverage (Supportan® Drink Cappuccino). The addition of the control beverage provides energy intake and limits the noise that the beverage may contribute to the metabolic profile in urine and serum.
Study NCT06449170 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Guava
Description: In this intervention, subjects consumed 3 guavas and 150 ml of control beverage (Supportan® Drink Cappuccino). The addition of the control beverage provides energy intake and limits the noise that the beverage may contribute to the metabolic profile in urine and serum.
Study NCT06449170 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Amaranth
Description: In this intervention, subjects consumed 1/2 cup of amaranth and 150 ml of control beverage (Supportan® Drink Cappuccino). The addition of the control beverage provides energy intake and limits the noise that the beverage may contribute to the metabolic profile in urine and serum.
Study NCT06449170 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Control Beverage (Supportan Drink ® Capuccino)
Description: In this intervention, subjects consumed 290ml of Supportan Drink ® Capuccino to act as a control for the metabolomic profiling in urine and serum.
Study NCT04888351 — intervention group
Intervention type: OTHER
Intervention: Comparison of complications between mastectomies with IBR and mastectomies without IBR
Description: Precocious complications (less than 3 months after surgery) are classified with Clavien's classification : hematoma, seroma, stitches, antibiotics, transfusion.~Tardive complications (after 3 months until 1 year) are more specifics : hematoma, seroma, tardive infections, asymmetry, removing of implant, breaking up of implant, skin necrosis, capsular contractures, implant loss, chronic pain.
Study NCT04888351 — intervention group
Intervention type: OTHER
Intervention: To analyze variations of number of patients eligibles to IBR
Description: Including patients with differents classic risk factors : T3, T4, tobacco, diabetes, overweight and obesity, hypertension, age over 70, thoracic irradiation in the past